Hemophilia A Without Inhibitor Clinical Trials
2 recruiting trials for Hemophilia A Without Inhibitor. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Hemophilia A Without Inhibitor clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 4 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by Kathelijn Fischer (1), Investigación en Hemofilia y Fisioterapia (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Emicizumab - PK-guided dose reduction (other, 1 trial), followed by Emicizumab - Dosis continuation group, Emicizumab - Dose adjustment group.
Track Hemophilia A Without Inhibitor trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Pharmacokinetic-guided Dosing of Emicizumab
The goal of this multicentre, prospective, open-label, cross-over clinical study is to determine whether individualized PK-guided dosing of emicizumab is non-inferior to...
Multidimensional Assessment of Chronic Pain in Severe Haemophilia A
Introduction: Haemophilia is a congenital coagulopathy characterised by haemarthrosis, mainly in the knees, ankles and elbows. Prophylactic treatment is the most effective...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Hemophilia A Without Inhibitor, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Hemophilia A Without Inhibitor, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Hemophilia A Without Inhibitor, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.